Compare Invesco NASDAQ 100 ETF (QQQM) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco NASDAQ 100 ETF vs Summit Therapeutics Inc — how do they compare? Invesco NASDAQ 100 ETF trades at $294.97, while Summit Therapeutics Inc trades at $17.52 (market cap $13.79B). The key difference: Invesco NASDAQ 100 ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| QQQM | SMMT | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $307.23 | $26.38 |
52-Week Low | $229.87 | $12.43 |
Market Cap | — | $13.79B |
Enterprise Value | — | $13.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQM trades at $295.76, down 0.1% with a bullish technical signal from moving averages. The ETF tracks the Nasdaq-100 index, offering diversified exposure to large-cap growth stocks. Recent news highlights QQQM's low expense ratio advantage over QQQ and its position as a core growth allocation option for investors seeking Nasdaq-100 exposure.
The outlook remains positive for long-term growth investors, with technical indicators supporting bullish momentum. Key risks include concentration in top holdings and market sensitivity to technology sector performance. The ETF's low-cost structure provides a competitive advantage for sustained investment.
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
